Sign in
Not yet recruitingNo phase

Early Detection of Perinatal Depression With Wearable Technology

Key facts

Who runs it
Women's College Hospital
Where
Canada1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
People taking part
10 people, planned
Started
Sept 2026
Expected to end
Nov 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Oura Ring (Photoplethysmography-based wearable ring)
  • EmbracePlus Watch (Electrodermal activity wristband sensor)
Record updated
25 August 2026

Who can take part

Age
16 years and older
Sex
Women only
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Age ≥ 16 years
  • Pregnant, 13-27 weeks gestation at enrollment
  • Previous diagnosis of major depressive disorder (MDD), confirmed by Mini International Neuropsychiatric Interview (MINI) (not necessarily perinatal onset)
  • Currently in remission (EPDS score < 9)
  • Access to a smartphone and internet, or willingness to use a study-provided device

Who cannot take part

  • Active alcohol or substance use disorder within the past 12 months
  • History of bipolar disorder or primary psychotic disorder
  • Physical condition preventing use of Oura Ring or EmbracePlus (expected to be rare)
  • Active suicidal ideation

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this feasibility study is to learn whether wearable devices and self-report surveys can help researchers better understand changes in mood during pregnancy and after birth in young pregnant individuals with a history of major depressive disorder. The study will also examine whether this type of monitoring is practical and acceptable for participants and clinicians. The main questions it aims to answer are:

Read full original descriptionShow less

* Can researchers successfully collect wearable and survey data throughout late pregnancy and the first 3 months after birth? * Do participants and clinicians find wearable-based monitoring easy to use and helpful? * Are changes in sleep, heart rate, activity, and other wearable data linked to mood changes during the perinatal period?

Researchers will compare 2 wearable devices, the Oura Ring and EmbracePlus, to see which device provides more complete and usable data.

Participants will:

* Wear either the Oura Ring or EmbracePlus device every day from the third trimester of pregnancy until 3 months after birth * Complete short daily and biweekly questionnaires about mood and wellbeing * Allow the wearable device to collect information such as sleep, heart rate, heart rate variability, and physical activity

The study will include 10 participants. Researchers will measure feasibility by looking at how many participants join the study and how much study data is completed. The study team hopes at least 70% of scheduled study activities data will be collected.

Researchers will also interview 5 participants and 4 reproductive psychiatry clinicians about their experiences using wearable monitoring. These interviews will explore ease of use, usefulness in clinical care, and how wearable data may fit into electronic medical records.

This study may help researchers develop future tools that can predict the risk of perinatal depression earlier and support more personalized care during pregnancy and after birth.

The 2 groups in the trial

  • Oura RingTreatment being tested

    Participants randomized to this arm will wear the Oura Ring continuously from the third trimester of pregnancy through three months postpartum. The device will collect sleep, activity, heart rate, and heart rate variability data passively, alongside daily and biweekly self-report measures.

    Treatment: Oura Ring (Photoplethysmography-based wearable ring)

  • EmbracePlusExisting treatment, for comparison

    Participants randomized to this arm will wear the EmbracePlus smartwatch continuously from the third trimester of pregnancy through three months postpartum. The device will collect sleep, activity, heart rate, heart rate variability, and electrodermal activity data passively, alongside daily and biweekly self-report measures.

    Treatment: EmbracePlus Watch (Electrodermal activity wristband sensor)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Biometrics in Longitudinal Uptake for Early Monitoring and Assessing Perinatal Patterns of Emotions in Depression
Record updated
25 August 2026